We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Qiagen Launches Portfolio of Environmentally Friendly Nucleic Acid Extraction Kits

By LabMedica International staff writers
Posted on 21 Jan 2022
Print article
Image: QIAGEN\'s new QIAwave products (Photo courtesy of QIAGEN N.V.)
Image: QIAGEN\'s new QIAwave products (Photo courtesy of QIAGEN N.V.)

QIAGEN N.V. (Venlo, Netherlands) has launched its new QIAwave product line of three nucleic acid extraction kits that use fewer components and produce less waste than existing ones. They are the first of their type to use both recycled plastics and space-saving chemical concentrates.

The QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and QIAwave Plasmid Miniprep Kit use up to 63% less plastic and up to 42% less cardboard than QIAGEN’s most popular kits for extracting DNA, RNA and plasmid DNA from samples. That makes them a more sustainable alternative to existing products – a major step in reducing the environmental impact of QIAGEN’s overall portfolio.

The new QIAwave products feature fewer components, waste tubes made from 100% recycled plastic, and suitable buffer concentrates in smaller bottles, rather than ready-to-go mixes. More compact kits and new ways of packing them reduce the amount of cardboard needed to box them up.

“QIAwave products are designed in collaboration with our customers to tackle the persistent problem of laboratory waste faced by scientists all over the world,” said Thomas Schweins, Senior Vice President, Head of Life Sciences. “These three kits are the first in a wave of continuous improvements and product evolutions that will reduce the environmental footprint of our products, while still delivering the same QIAGEN quality.”

Related Links:
QIAGEN N.V. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.